Last reviewed · How we verify
NCT05858671
Determining the Lipid Lowering Effect of Fenugreek Seed Tea
NA trial testing Fenugreek Seed Tea in Hyperlipidemias in 67 participants. Completed in 26 June 2024.
26 June 2024
Quick facts
| Lead sponsor | Queen's University, Belfast |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 67 |
| Start date | 29 May 2023 |
| Primary completion | 26 June 2024 |
| Estimated completion | 26 June 2024 |
| Sites | 2 locations across United Kingdom |
Drugs / interventions tested
- Fenugreek Seed Tea
- Black Tea — full drug profile →
Conditions studied
- Hyperlipidemias — all drugs for Hyperlipidemias →
Sponsor
Queen's University, Belfast
Who can join
Adults 18 to 70, any sex, with Hyperlipidemias. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this randomized clinical trial is to investigate the lipid-lowering effect of fenugreek seed consumed as a tea in patients with hyperlipidaemia, but without diabetes over an 8-week intervention period. Alteration of plasma microRNAs (e.g. microRNA-122 and microRNA-34a) will further be analysed for establishing as non-invasive therapeutic biomarkers of hyperlipidaemia. Participants will be asked to attend three study at baseline, 4 and 8 weeks in the Centre for Public Health. Each visit will involve the collection of demographic information, anthropometric measurements, blood pressure and fasting blood samples. Participants allocated to intervention or control will be asked to self-administer tea twice a day at a 12 hour interval over the 8-week study period. Researchers will compare the results of the consumption of fenugreek seed tea to the control black tea to see if fenugreek has any effect on lipid levels.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05858671
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperlipidemias
Currently open trials in the same condition.
- NCT06903897 — Social Needs Screening and Chronic Diseases Study (WE CARE) · NA · recruiting
- NCT06049420 — Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients · NA · recruiting
- NCT06461273 — Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome · NA · active not recruiting
- NCT06094491 — Virtual Diabetes Group Visits Across Health Systems · Phase 2 · active not recruiting
- NCT06055036 — Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention · NA · recruiting
Other Queen's University, Belfast trials
Trials by the same sponsor.
- NCT07373041 — Heart Failure Carer Support Programme: Implementation Testing in the UK. · NA · not yet recruiting
- NCT07482839 — Feasibility Study of a Compassionate Mindful Resilience (CMR) Intervention to Improve Mental Health Well-being Outcomes · NA · not yet recruiting
- NCT07333924 — Randomised Study Within a Review (SWAR) to Compare Communication of the Findings of Systematic Reviews to the Public by · Phase 3 · completed
- NCT06896799 — Determining the Effect of Food Ordering on Blood Glucose In Gestational Diabetes Mellitus (DEFI-GDM) · NA · recruiting
- NCT06749327 — Dissecting the Roles of High-quality Diets and Ultra Processed Foods on Cardiometabolic Health · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05858671 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Queen's University, Belfast
- Last refreshed: 7 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05858671.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing